CFTR and cystic fibrosis: We demonstrated that our AsCas12a-based gene correction strategy efficiently corrects the splicing pattern in human primary airway epithelial cells and rescued endogenous CFTR function in patient derived intestinal organoids, which are recognized as a highly valuable preclinical model to predict ex vivo therapeutic efficacy in CF patients47, providing an important milestone for future clinical trials.